Posts tagged: GlaxoSmithKline

Betaville Intelligence

RARE ALERT: GlaxoSmithKline said to ... - Part 5

Tuesday, 22 March 2022, 4:24 pm

The European-based investor group seeking to persuade the board of Aurinia Pharmaceuticals to carry out a strategic review has appointed a US lawyer to manage an action group for other investors looking to back its activist campaign.

The move comes as the investment consortium, led by the Switzerland-based MKT Tactical Fund, recently wrote a second letter to the chairman of Aurinia, George Milne Junior...

Read more...

GlaxoSmithKline said to be eyeing £1 billion plus takeover bid for Theravance Biopharma, reports The Times

Friday, 11 February 2022, 8:21 am

Has GlaxoSmithKline truly given up its pursuit of Aurinia Pharmaceuticals, the US-listed drug developer?

Last year Betaville Intelligence reported that GSK was one of the pharmaceutical giants circling Aurinia but now The Times is reporting the FTSE 100-listed group is looking at a different takeover target...

Read more...

Unilever may be a target for activist such as Nelson Peltz, reports FT - Part 3

Sunday, 23 January 2022, 12:37 pm

The Unilever might be a target for Nelson Peltz theory was first aired last summer but now it appears to be have become fact.

Indeed, hacks at the venerable Financial Times have dug a decent scoop today about Peltz building a stake after the botched £50 billion tilt GlaxoSmithKline's consumer division. Below is a link to the FT piece:..

Read more...

Unilever bids £50 billion for GlaxoSmithKline's consumer arm, reveals The Sunday Times - Part 2

Monday, 17 January 2022, 9:57 pm

Well, it looks like Ian "Kingy" King is first out of the traps to highlight something little old Betaville had been ruminating on with an old City contact over a few glasses down the pub this evening.

In a piece today King, a former City editor of The Times and now business presenter at Sky News, argues Unilever may have accidently put itself in play after attempting to buy GlaxoSmithKline's consumer division for £50 billion. Below is the link:..

Read more...

Betaville Intelligence

RARE ALERT: GlaxoSmithKline said to ...

Thursday, 28 October 2021, 3:04 pm

FTSE 100-listed GlaxoSmithKline, Switzerland-based Roche and Japan's Otsuka Pharmaceutical are all rumoured to be the large pharmaceutical companies involved in the strategic review being carried by Aurinia Pharmaceuticals, the US-listed rare disease drug developer.

People following the situation have heard speculation Goldman Sachs is advising Aurinia on the strategic review...

Read more...